Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis

Clin Immunol. 2012 Feb;142(2):176-93. doi: 10.1016/j.clim.2011.10.003. Epub 2011 Oct 26.

Abstract

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and adolescents. Immunomodulatory drugs are used frequently in its treatment. Using the nominal group technique (NGT) and Delphi method, we created a multidisciplinary, evidence- and consensus-based treatment guideline for JIA based on a systematic literature analysis and three consensus conferences. Conferences were headed by a professional moderator and were attended by representatives who had been nominated by their scientific societies or organizations. 15 statements regarding drug therapy, symptomatic and surgical management were generated. It is recommended that initially JIA is treated with NSAID followed by local glucocorticoids and/or methotrexate if unresponsive. Complementing literature evidence with long-standing experience of caregivers allows creating guidelines that may potentially improve the quality of care for children and adolescents with JIA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Arthritis, Juvenile / therapy*
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Consensus Development Conferences as Topic*
  • Evidence-Based Medicine
  • Glucocorticoids / therapeutic use
  • Humans
  • Methotrexate / therapeutic use*
  • Practice Guidelines as Topic
  • Young Adult

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Glucocorticoids
  • Methotrexate